Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0016053 (fibromyalgia)
 4,687 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The purpose of this study was to investigate the association among daily stressors, cognitive rumination, and fibromyalgia symptoms using time-series methodology and to determine whether autocorrelation was present in the self-report data. Twelve female fibromyalgia subjects monitored their daily level of stressors, cognitive rumination, and fibromyalgia symptoms for 30-35 days. Time-series regression analyses indicated that there was a positive association between previous-day stressors and fibromyalgia symptoms for one subject and between previous-day cognitive rumination and fibromyalgia symptoms for four subjects. For 7 out of 12 subjects autocorrelation was present, and generalized least-squares methods were used with these subjects. These results indicate that ordinary least-squares methods may often not be appropriate for within-subject designs with self-report data. These results also question the often reported stressor-physical symptom association. This study illustrates a useful methodology and analysis to investigate psychosocial-physical symptom associations.
 ...
PMID:Fibromyalgia: a time-series analysis of the stressor-physical symptom association. 148 79

Somatization disorder (SD) is commonly seen in medical clinics and is associated with significant impairment in functioning as well as excessive utilization of health care. While antidepressants have been studied in some functional somatic syndromes such as fibromyalgia and chronic fatigue, there are no pharmacologic treatment studies of SD itself. In this prospective, 8-week, open-label study, 15 patients diagnosed with either full SD or abridged somatization, by Escobar's criteria (four unexplained physical symptoms for men or six for women), were given nefazodone, titrated to 150 mg bid. The primary outcomes included measures of physical symptom severity (visual analogue scale), functioning (SF-36), and overall improvement (CGI). Fourteen of the 15 patients achieved the target dose of 300 mg/day and completed the trial. 73% of the patients were rated as improved on the CGI, 79% improved on the self-rated visual analogue scale and 73% of the patients improved on the SF-36. There was significant improvement for the whole group (prepost) on the SF-36, as well as on the HAM-D and the HAM-A. Of the nine patients with a categorical depression diagnosis, 55% of them were rated as improved on the CGI, and 67% improved on both the VAS and the SF-36. Of the six nondepressed patients, 67% were rated as improved on the CGI, 83% improved on the SF-36, and 50% improved on the VAS. Adverse events were generally mild and resulted in only one discontinuation. Although these data need to be confirmed in a larger, double-blind, placebo-controlled trial, they suggest that patients with SD will accept and tolerate therapy with nefazodone and that nefazodone may be a useful treatment for these patients.
 ...
PMID:Treatment of somatization disorder with nefazodone: a prospective, open-label study. 1179 53

The Fibromyalgia Impact Questionnaire (FIQ) is the most frequently used questionnaire in patients with fibromyalgia in the last 20 years. Recently, a revised version of the FIQ has been published. In this study, we examined the factor structure of the original version using explorative and confirmative factor analyses in a representative group of about 500 Dutch and Belgian patients with fibromyalgia, in which the work-related item was excluded. The FIQ consisting of a three-factor structure with a functional domain (ten items), physical symptom domain (six items), and mental symptom domain (two items), which is the most accurate. From the data presented, it is concluded that the FIQ is a solid, worldwide-used questionnaire with a history of 20 years consisting of three domains. When constructing a revised FIQ, the results of this study can be incorporated.
 ...
PMID:Not throwing out the baby with the bathwater: lessons from the Fibromyalgia Impact Questionnaire. 2319 33